Interestingly, we found that T-cell activation, as documented by up-regulation of CD25, CD137, and CD69, by the TRAIL-R2/CD3 scDb was strictly dependent on the presence of TRAIL-R2+ tumor cells in the experimental assay. The gene discussed is CD69; the disease is neoplasm.